No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 0.725
- +0.025+3.63%
Close May 1 16:00 ET
10.30MMarket Cap0.35P/E (TTM)
0.725High0.657Low60.17KVolume0.670Open0.700Pre Close41.03KTurnover0.64%Turnover Ratio0.35P/E (Static)14.20MShares1.89052wk High0.61P/B6.81MFloat Cap0.42052wk Low--Dividend TTM9.39MShs Float184.000Historical High--Div YieldTTM9.76%Amplitude0.420Historical Low0.681Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Announced the Publication of a New Study Reinforcing the Clinical Association of Its CCL24 Target With Disease Severity and Mortality in Patients With Systemic Sclerosis
Express News | Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) today reported that the European Patent Office has granted a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation.
Express News | Oppenheimer Maintains Perform on Chemomab Therapeuticsto Perform
Comments
Watching for the data
$Chemomab Therapeutics(CMMB.US$ Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
1
Therapeutics Company Awarded Patent For Breakthrough Liver Disease Treatment
Breakthrough in Liver Disease Treatment: Chemomab's CM-101 Secures New European Patent.
In the realm of medical science, groundbreaking advancements often mark pivotal moments in the fight against debilitating diseases. One such recent development in the battle against Primary Sclerosing Cholangitis (PSC), a rare and potentially fatal liver disease, has emerged from the labs of Chemomab Therapeutics. The company has been...
In the realm of medical science, groundbreaking advancements often mark pivotal moments in the fight against debilitating diseases. One such recent development in the battle against Primary Sclerosing Cholangitis (PSC), a rare and potentially fatal liver disease, has emerged from the labs of Chemomab Therapeutics. The company has been...
Pretty nice!
$Chemomab Therapeutics(CMMB.US$ Waiting for the rest of the numbers! (((((. Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.26) per share. This is a 63.89 percent increase over losses of $(0.72) per share from the same period last year. )))))
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg